87 related articles for article (PubMed ID: 21607331)
1. The tris formulation of Fluorouracil is more cardiotoxic than the sodium-salt formulations.
Lemaire L; Maletmartino M; Martino R; Deforni M; Lasserre B
Oncol Rep; 1994 Jan; 1(1):173-4. PubMed ID: 21607331
[TBL] [Abstract][Full Text] [Related]
2. [Cardiotoxicity of 5-fluorouracil: a question of formulation].
Lemaire L; Arellano M; Malet-Martino MC; Martino R; De Forni M
Bull Cancer; 1994 Dec; 81(12):1057-9. PubMed ID: 7742593
[TBL] [Abstract][Full Text] [Related]
3. Hydrolytic pathway of 5-fluorouracil in aqueous solutions for clinical use.
Legay R; Massou S; Azéma J; Martino R; Malet-Martino M
J Pharm Biomed Anal; 2014 Sep; 98():446-62. PubMed ID: 25038499
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug.
Lemaire L; Malet-Martino MC; de Forni M; Martino R; Lasserre B
Br J Cancer; 1992 Jul; 66(1):119-27. PubMed ID: 1637660
[TBL] [Abstract][Full Text] [Related]
5. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate.
Arellano M; Malet-Martino M; Martino R; Gires P
Br J Cancer; 1998; 77(1):79-86. PubMed ID: 9459149
[TBL] [Abstract][Full Text] [Related]
6. 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.
Arellano M; Malet-Martino M; Martino R; Spector T
Br J Cancer; 1997; 76(9):1170-80. PubMed ID: 9365165
[TBL] [Abstract][Full Text] [Related]
7. Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump.
Fournet A; Gilard V; Malet-Martino M; Martino R; Canal P; De Forni M
Cancer Chemother Pharmacol; 2000; 46(6):501-6. PubMed ID: 11138464
[TBL] [Abstract][Full Text] [Related]
8. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
[TBL] [Abstract][Full Text] [Related]
9. A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives.
Lamberti M; Porto S; Zappavigna S; Addeo E; Marra M; Miraglia N; Sannolo N; Vanacore D; Stiuso P; Caraglia M
Toxicol Lett; 2014 Jun; 227(3):151-6. PubMed ID: 24704391
[TBL] [Abstract][Full Text] [Related]
10. Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Franck C; Malfertheiner P; Venerito M
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28536214
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic cardiotoxicity associated with 5-fluorouracil.
Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
[TBL] [Abstract][Full Text] [Related]
13. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot.
Kim DY; Kwon DY; Kwon JS; Park JH; Park SH; Oh HJ; Kim JH; Min BH; Park K; Kim MS
Biomaterials; 2016 Apr; 85():232-45. PubMed ID: 26874285
[TBL] [Abstract][Full Text] [Related]
15. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
[TBL] [Abstract][Full Text] [Related]
17. Application of hydrotropy to transdermal formulations: hydrotropic solubilization of polyol fatty acid monoesters in water and enhancement effect on skin permeation of 5-FU.
Takahashi K; Komai M; Kinoshita N; Nakamura E; Hou XL; Takatani-Nakase T; Kawase M
J Pharm Pharmacol; 2011 Aug; 63(8):1008-14. PubMed ID: 21718283
[TBL] [Abstract][Full Text] [Related]
18. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.
Thomas AM; Kapanen AI; Hare JI; Ramsay E; Edwards K; Karlsson G; Bally MB
J Control Release; 2011 Mar; 150(2):212-9. PubMed ID: 21094191
[TBL] [Abstract][Full Text] [Related]
19. Risk of microbial contamination with multiple use of 5-fluorouracil vials.
Mora JS; Cevallos V; Whitcher JP
J Glaucoma; 1996 Dec; 5(6):371-4. PubMed ID: 8946292
[TBL] [Abstract][Full Text] [Related]
20. Increased iron content in rat myocardium after 5-fluorouracil chronic administration.
Millart H; Kantelip JP; Platonoff N; Descous I; Trenque T; Lamiable D; Choisy H
Anticancer Res; 1993; 13(3):779-83. PubMed ID: 8317911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
